Acquired aplastic anemia developing myelodysplastic syndrome/acute myeloid leukemia: clinical analysis of nineteen patients and literatures review.

Li MA; Xingxin LI; Jing Zhang; Yingqi Shao; Neng Nie; Zhendong Huang; Meili GE; Yizhou Zheng; Dongxia QU; Jun Shi

Return

Acquired aplastic anemia developing myelodysplastic syndrome/acute myeloid leukemia: clinical analysis of nineteen patients and literatures review.

Author: Li MA ¹ ; Xingxin LI ¹ ; Jing ZHANG ¹ ; Yingqi SHAO ¹ ; Neng NIE ¹ ; Zhendong HUANG ¹ ; Meili GE ¹ ; Yizhou ZHENG ¹ ; Dongxia QU ¹ ; Jun SHI ¹
Author Information

1. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
Publication Type:Journal Article
MeSH: Anemia, Aplastic; Chromosome Deletion; Chromosomes, Human, Pair 7; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
From: Chinese Journal of Hematology 2015;36(3):216-220
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo analyze the clinical features of clonal evolution of acquired aplastic anemia (AA) into myelodysplastic syndrome/acute myeloid leukemia (AML) and review of literatures.
METHODSAA developing MDS/AML patients between December 1994 and December 2011 enrolled into this study to analyze their clinical characteristics.
RESULTSDuring the median follow-up of 49(15-97) months, 19 patients evolved to MDS/AML, of whom 10, 8 and 1 were from VSAA, SAA and NSAA subgroups, respectively. The median G-CSF therapy was 270(29-510) days. There were monosomy 7 in 11(57.9%) of 19 patients with AA evolved to MDS/AML. The median AA evolved to MDS/AML was 33(11-88) months. The median MDS/AML transformation in responders (54.2 months) was significantly longer than of non-responders (25.7 months, P<0.01).
CONCLUSIONAA patients could evolved into MDS/AML concomitant with abnormal karotype and worse prognosis.